Pathway / Interaction Diagram
flowchart LR
N1["ESRRG Gene"]
N1 -->|"regulates"| N2["DKK1"]
N1 -->|"associated with"| N3["Alzheimer's disease"]
N1 -->|"regulates"| N4["neurodegenerative disease"]
N1 -->|"associated with"| N5["Huntington"]
N1 -->|"inhibits"| N6["Synucleinopathy"]
N1 -->|"encodes"| N5["Huntington"]
style N1 fill:#006494,stroke:#333,color:#e0e0e0,stroke-width:2px
Overview
ESRRG (Estrogen-Related Receptor Gamma), also known as ERRγ or NR3B3 (Nuclear Receptor Subfamily 3 Group B Member 3), is an orphan nuclear receptor that functions as a transcriptional regulator of metabolism, mitochondrial biogenesis, and cellular energy homeostasis. It is encoded by the ESRRG gene located on chromosome 1q41 (1q41), spanning approximately 50 kb and consisting of 13 exons. ESRRG is a member of the estrogen-related receptor (ERR) subfamily of nuclear receptors, which includes [ESRRA](/genes/esrra) (ERRα) and [ESRRB](/genes/esrrb) (ERRβ) [@handschin2005].
Unlike classical steroid hormone receptors, ERRγ does not bind natural estrogens with high affinity and is considered an orphan receptor. However, it shares structural features with estrogen receptors and can regulate similar target genes involved in energy metabolism, mitochondrial function, and cellular survival. ESRRG is widely expressed in tissues with high metabolic demand, including brain, heart, skeletal muscle, and kidney [@schreiber2003].
<div class="infobox infobox-gene">
...Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Overview
ESRRG (Estrogen-Related Receptor Gamma), also known as ERRγ or NR3B3 (Nuclear Receptor Subfamily 3 Group B Member 3), is an orphan nuclear receptor that functions as a transcriptional regulator of metabolism, mitochondrial biogenesis, and cellular energy homeostasis. It is encoded by the ESRRG gene located on chromosome 1q41 (1q41), spanning approximately 50 kb and consisting of 13 exons. ESRRG is a member of the estrogen-related receptor (ERR) subfamily of nuclear receptors, which includes [ESRRA](/genes/esrra) (ERRα) and [ESRRB](/genes/esrrb) (ERRβ) [@handschin2005].
Unlike classical steroid hormone receptors, ERRγ does not bind natural estrogens with high affinity and is considered an orphan receptor. However, it shares structural features with estrogen receptors and can regulate similar target genes involved in energy metabolism, mitochondrial function, and cellular survival. ESRRG is widely expressed in tissues with high metabolic demand, including brain, heart, skeletal muscle, and kidney [@schreiber2003].
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | ESRRG |
| Full Name | Estrogen-Related Receptor Gamma |
| Chromosomal Location | 1q41 |
| NCBI Gene ID | 2624 |
| OMIM ID | 605515 |
| Ensembl ID | ENSG00000125520 |
| UniProt ID | Q9UH77 |
| Encoded Protein | Estrogen-related receptor gamma |
| Gene Type | Protein-coding |
| Protein Family | Nuclear receptor family, ERR subfamily |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, metabolic disorders |
</div>
Structure and Function
Protein Structure
ESRRG is a nuclear receptor protein composed of multiple functional domains:
N-terminal domain (A/B domain): Contains the activation function-1 (AF-1) region responsible for transcriptional activation
DNA-binding domain (C domain): Contains two C4-type zinc fingers that enable binding to estrogen-related response elements (ERREs)
Dimerization domain (D domain): Flexible hinge region allowing receptor dimerization
Ligand-binding domain (E/F domain): Contains the activation function-2 (AF-2) region and mediates interactions with coactivatorsThe DNA-binding domain recognizes palindromic sequences known as ERREs (TNAAGGTCA) and half-sites (AGGTCA) with high specificity. ESRRG can bind DNA as a monomer, homodimer, or heterodimer with other nuclear receptors including [PPARG](/genes/pparg), [PPARA](/genes/ppara), and [RORA](/genes/rora) [@eichner2019].
Transcriptional Regulation
ESRRG functions as a transcriptional activator or repressor depending on cellular context and cofactor availability:
Primary Targets:
- Mitochondrial biogenesis genes (TFAM, Tfam, NRF1, NRF2)
- Metabolic enzymes (PDH, SDH, COX subunits)
- Fatty acid oxidation enzymes (CPT1, MCAD, LCAD)
- Gluconeogenic enzymes (PEPCK, G6Pase)
- Uncoupling proteins (UCP2, UCP3)
Coactivator Interactions:
- [PGC-1A](/genes/pgc1a) (PPARGC1A) - master regulator of mitochondrial biogenesis
- [NCOA1](/genes/ncoa1) (SRC-1), NCOA2 (SRC-2), NCOA3 (SRC-3)
- PGC-1β (PPARGC1B)
- CBP/p300 (CREBBP, EP300)
Receptor Interactions
ESRRG interacts with multiple nuclear receptors and transcription factors:
| Protein | Interaction Type | Functional Consequence |
|---------|-----------------|------------------------|
| [PGC-1α](/proteins/pgc-1alpha) | Coactivator | Mitochondrial biogenesis activation |
| [PPARα](/proteins/ppara) | Heterodimer | Fatty acid oxidation |
| [PPARγ](/proteins/ppar) | Heterodimer | Lipid metabolism |
| [RORα](/proteins/rora) | Heterodimer | Circadian gene regulation |
| [Nurr1](/genes/nurr1) | Cross-talk | Dopaminergic neuron function |
| [ERRα](/genes/esrra) | Heterodimer | Metabolic gene regulation |
Role in Neurodegeneration
Alzheimer's Disease
ESRRG is increasingly recognized as an important player in Alzheimer's disease pathogenesis, particularly through its effects on mitochondrial function, energy metabolism, and neuronal survival [@gong2018].
Mitochondrial Dysfunction:
ESRRG is a key regulator of mitochondrial biogenesis through its transcriptional activation of PGC-1α and downstream mitochondrial genes. In AD brain, ESRRG expression is altered, contributing to the well-documented mitochondrial dysfunction [@zhang2016]:
- Reduced ESRRG expression correlates with decreased mitochondrial DNA copy number
- Impaired PGC-1α/ESRRG signaling leads to reduced TFAM and mitochondrial transcription factors
- Decreased complex IV (COX) activity in ESRRG-deficient neurons
- Impaired mitochondrial respiration and ATP production
Amyloid Pathology:The amyloid-β peptide, the primary component of amyloid plaques in AD, interacts with ESRRG signaling:
- Aβ treatment reduces ESRRG expression in neurons
- ESRRG activation protects against Aβ-induced mitochondrial dysfunction
- ESRRG modulates amyloid precursor protein (APP) processing
- Cross-talk between ESRRG and amyloidogenic pathways
Tau Pathology:ESRRG plays a role in tauopathy through multiple mechanisms [@correa2017]:
- ESRRG regulates kinases and phosphatases involved in tau phosphorylation
- PGC-1α/ESRRG axis affects tau aggregation and clearance
- Mitochondrial dysfunction induced by ESRRG alterations contributes to tau pathology
- ESRRG deficiency exacerbates tau-induced neurodegeneration
Neuroinflammation:ESRRG modulates neuroinflammatory responses in AD [@fan2020]:
- ESRRG regulates anti-inflammatory gene expression
- Microglial ESRRG affects cytokine production
- ESRRG deficiency leads to increased neuroinflammation
- Therapeutic ESRRG activation may reduce microglial activation
Energy Metabolism and synaptic dysfunction:The brain's high energy demands make ESRRG particularly important:
- ESRRG regulates glucose metabolism and neuronal ATP production
- Synaptic activity requires proper mitochondrial function maintained by ESRRG
- ESRRG deficiency leads to synaptic protein loss
- Impaired long-term potentiation in ESRRG-modified models
Parkinson's Disease
In Parkinson's disease, ESRRG is particularly relevant due to its role in dopaminergic neuron survival and mitochondrial function [@venturini2020].
Dopaminergic Neuron Vulnerability:
ESRRG is highly expressed in dopaminergic neurons of the substantia nigra:
- ESRRG maintains mitochondrial function in [vulnerable dopamine neurons](/cell-types/vulnerable-substantia-nigra-dopamine-neurons)
- ESRRG expression is reduced in PD substantia nigra
- ESRRG protects against 6-OHDA and MPTP toxicity
- [Nurr1](/genes/nurr1) and ESRRG cross-talk in dopaminergic neurons
Mitochondrial Complex Activity:ESRRG regulates components of the electron transport chain:
- ESRRG activates complex I (NADH dehydrogenase) subunit expression
- Complex IV (COX) regulation through ESRRG
- Regulation of ATP synthase subunits
- Coordination of mitochondrial DNA replication
Oxidative Stress:ESRRG protects against oxidative stress, a key contributor to PD:
- ESRRG regulates antioxidant enzyme expression (SOD, catalase, GPx)
- [Uncoupling protein 2](/genes/ucp2) (UCP2) regulation by ESRRG
- Mitochondrial ROS production modulated by ESRRG
- Protection against dopamine-induced oxidative damage
α-Synuclein Interaction:ESRRG relates to α-synuclein pathology:
- ESRRG affects mitochondrial quality control of α-synuclein
- Autophagy regulation through ESRRG/PGC-1α axis
- ESRRG deficiency exacerbates α-synuclein aggregation
- Therapeutic potential of ESRRG activation in synucleinopathies
LRRK2 Connection:Many PD patients have LRRK2 mutations, and ESRRG interacts with LRRK2 pathway:
- LRRK2 G2019S affects mitochondrial function through ESRRG
- ESRRG may be downstream of LRRK2 signaling
- Combined targeting may provide therapeutic benefit
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS):
- ESRRG expression altered in motor neuron disease
- Mitochondrial dysfunction in ESRRG-deficient models
- Therapeutic potential in ALS models
Huntington's Disease:
- ESRRG regulates mutant huntingtin toxicity
- Mitochondrial dysfunction in HD involves ESRRG
- Energy metabolism alterations in ESRRG context
Frontotemporal Dementia:
- ESRRG in tauopathy contexts
- Mitochondrial involvement in FTD
Prion Diseases:
- ESRRG in prion-induced neurodegeneration
- Metabolic dysfunction in prion disease
Molecular Mechanisms
Signaling Pathways
PGC-1α Axis:
The primary mechanism of ESRRG action involves PGC-1α coactivation [@handschin2005]:
ESRRG binds to PGC-1α through LBD interaction
PGC-1α recruitment enhances transcriptional activity
PGC-1α/ESRRG complex activates target genes
Mitochondrial biogenesis and function are enhancedERR Response Elements (ERREs):
ESRRG directly regulates gene expression through:
Binding to palindromic ERRE sequences (TNAAGGTCA)
Recruitment of coactivators (PGC-1α, SRC-1, CBP/p300)
Histone acetylation and chromatin remodeling
Target gene transcription activationCross-talk with Other Nuclear Receptors:
PPAR Pathway:
- ESRRG forms heterodimers with PPARα and PPARγ
- Coordinated regulation of fatty acid metabolism
- Common target genes include CPT1, FABP, and fatty acid transporters
ROR Pathway:
- ESRRG interacts with RORα and RORγ
- Circadian gene regulation
- Shared metabolic targets
Nurr1 Pathway:
- ESRRG and Nurr1 cooperate in dopaminergic neurons
- Common targets include mitochondrial genes
- Coordinate neuroprotection
Cell Type-Specific Effects
Neurons:
ESRRG is critical for neuronal survival:
- High expression in cortex, hippocampus, and cerebellum
- Regulation of neuronal mitochondrial content
- Protection against excitotoxicity
- Axonal mitochondrial transport support
Astrocytes:ESRRG in glial cells:
- Metabolic support of neurons
- Regulation of astrocyte mitochondrial function
- Neuroinflammation modulation
Microglia:ESRRG affects immune cells:
- Inflammatory cytokine regulation
- Phagocytic activity modulation
- Migration and activation
Oligodendrocytes:ESRRG in white matter:
- Myelination support
- Energy metabolism for myelin production
Expression Patterns
Brain Regional Distribution
ESRRG shows region-specific expression in the brain:
| Brain Region | Expression Level | Functional Implication |
|--------------|-----------------|------------------------|
| Cerebral Cortex | High | Cognitive function |
| Hippocampus | High | Memory and learning |
| Cerebellum | High | Motor coordination |
| Substantia Nigra | Moderate-High | Dopaminergic neuron function |
| Basal Ganglia | Moderate | Movement control |
| Brainstem | Moderate | Vital functions |
Cellular Localization
- Neuronal cell bodies: High expression in pyramidal and Purkinje cells
- Axons and dendrites: Mitochondrial localization
- Glial cells: Astrocyte and microglial expression
- Synapses: Presynaptic and postsynaptic localization
Developmental Expression
ESRRG expression changes across the lifespan:
- Embryonic development: Early expression in neural tube
- Postnatal development: Increased expression during brain maturation
- Adult brain: Sustained high expression
- Aging: Decreased expression in aged brain
- Disease: Altered expression in neurodegeneration
Interactions with Other Pathways
Glucose Metabolism:
- Regulation of glycolytic enzymes
- Gluconeogenesis control
- Insulin sensitivity modulation
- Glucose transporter expression
Lipid Metabolism:
- Fatty acid oxidation activation
- Lipogenesis regulation
- Cholesterol metabolism
- Ketone body utilization
Mitochondrial Dynamics:
- Biogenesis through PGC-1α
- Fusion and fission regulation
- mtDNA maintenance
- Quality control mechanisms
Cellular Stress Response
Oxidative Stress:
- Antioxidant enzyme regulation
- ROS scavenging
- Mitochondrial protection
- Nrf2 pathway cross-talk
Endoplasmic Reticulum Stress:
- Unfolded protein response
- Calcium homeostasis
- Apoptosis regulation
DNA Damage Response:
- Genomic stability maintenance
- Repair gene regulation
- Cell cycle control
Therapeutic Implications
Targeting ESRRG
Agonist Development:
Small molecule ESRRG agonists are being investigated:
GSK4716: Selective ERRγ agonist
- Enhances mitochondrial biogenesis
- Protects against metabolic stress
- Neuroprotective in models
DY131: ERRβ/γ agonist
- Neuronal protection
- Mitochondrial function enhancement
CINT1: Novel ERRγ activator
- Under development for neurodegeneration
Therapeutic Strategies
Alzheimer's Disease:
- ESRRG agonists to restore mitochondrial function
- Combination with amyloid-targeting approaches
- Modulation of neuroinflammation
- Synaptic protection
Parkinson's Disease:
- Protect dopaminergic neurons
- Enhance mitochondrial complex activity
- Reduce oxidative stress
- Combined with LRRK2-targeted approaches
Challenges and Considerations
Blood-Brain Barrier: Drug delivery to CNS
Selectivity: Avoiding off-target effects
Dosage: Balancing efficacy and safety
Chronic treatment: Long-term therapy requirements
Biomarkers: Need for response monitoringCombination Therapies
ESRRG-based approaches may be combined with:
- [PGC-1α activators](/therapeutics/pgc1-alpha-targeted-therapies)
- Mitochondrial antioxidants
- Metabolic modulators
- Anti-inflammatory agents
Detection Methods
- qPCR: Measure ESRRG mRNA expression
- Western blot: Quantify ESRRG protein levels
- Immunohistochemistry: Localize ESRRG in brain sections
- ChIP-seq: Identify ESRRG binding sites
- RNA-seq: Profile ESRRG-dependent gene expression
Experimental Models
- Knockout mice: Esrrg-/- mice
- Conditional knockouts: Brain-specific deletion
- Transgenic models: ESRRG overexpression
- iPSC-derived neurons: Human neuronal models
- Organoid models: Brain organoid systems
Chemical Probes
- GSK4716: Agonist for in vitro studies
- C29: Inverse agonist
- XCT790: Inverse agonist
- 4-OHT: Partial agonist
Genetic Considerations
Polymorphisms
ESRRG genetic variants may influence:
- Neurodegenerative disease susceptibility
- Metabolic disease risk
- Response to therapeutic intervention
Regulatory Elements
- Promoter variants affecting transcription
- Enhancer elements in tissue-specific regulation
- 3' UTR variants affecting mRNA stability
Key Interactions Table
| Protein/Pathway | Interaction Type | Relevance to Neurodegeneration |
|-----------------|-----------------|--------------------------------|
| [PGC-1α](/proteins/pgc-1alpha) | Coactivator | Mitochondrial biogenesis |
| [ERRα](/genes/esrra) | Heterodimer | Metabolic regulation |
| [PPARα](/genes/ppara) | Heterodimer | Fatty acid oxidation |
| [Nurr1](/genes/nurr1) | Cross-talk | Dopaminergic function |
| [TFAM](/genes/tfam) | Target gene | Mitochondrial DNA |
| [UCP2](/genes/ucp2) | Target gene | Oxidative stress |
| Complex I | Target gene | Electron transport |
| Complex IV | Target gene | Electron transport |
See Also
- [Mitochondrial biogenesis](/mechanisms/mitochondrial-biogenesis)
- [Alzheimer's disease](/diseases/alzheimers-disease)
- [Parkinson's disease](/diseases/parkinsons-disease)
- [Energy metabolism](/mechanisms/energy-metabolism)
- [Nuclear receptor signaling](/mechanisms/nuclear-receptor-signaling)
- [ERRα](/genes/esrra)
- [ERRβ](/genes/esrrb)
- [PGC-1α](/proteins/pgc-1alpha)
- [Nurr1 pathway](/mechanisms/nurr1-nr4a2-pathway-parkinsons)
- [Mitochondrial dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
- [Oxidative stress in neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
External Links
- [Ensembl: ENSG00000125520](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125520)
- [NCBI Gene: ESRRG](https://www.ncbi.nlm.nih.gov/gene/2624)
- [GeneCards: ESRRG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ESRRG)
- [OMIM: ESRRG](https://omim.org/entry/605515)
- [UniProt: Q9UH77](https://www.uniprot.org/uniprot/Q9UH77)
- [Allen Brain Atlas: ESRRG](https://human.brain-map.org/microarray/search/show?search_term=ESRRG)
References
[Genetic association of ESRRG with Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Mootha et al., PGC-1alpha-responsive genes in oxidative phosphorylation (2003)](https://pubmed.ncbi.nlm.nih.gov/14583441/)
[Handschin & Spiegelman, Regulation of muscle metabolism by PGC-1alpha (2005)](https://pubmed.ncbi.nlm.nih.gov/16180233/)
[Wang et al., ERRalpha in mitochondrial biogenesis (2006)](https://pubmed.ncbi.nlm.nih.gov/16431910/)
[Huss et al., ERRalpha regulates mitochondrial respiration (2007)](https://pubmed.ncbi.nlm.nih.gov/17341580/)
[Schreiber et al., Differential expression of ERRalpha (2003)](https://pubmed.ncbi.nlm.nih.gov/12697057/)
[Eichner & Kallen, ERRgamma and metabolic diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31222270/)
[Roy et al., ERRgamma in brain development (2010)](https://pubmed.ncbi.nlm.nih.gov/20977443/)
[Kim et al., ERRgamma in neural stem cells (2013)](https://pubmed.ncbi.nlm.nih.gov/23517227/)
[Chang et al., ERRgamma regulates neuronal survival (2011)](https://pubmed.ncbi.nlm.nih.gov/21871957/)
[Gong et al., ERRgamma in Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30542296/)
[Zhang et al., Mitochondrial dysfunction in AD (2016)](https://pubmed.ncbi.nlm.nih.gov/26710579/)
[Correa et al., ERRgamma and PGC-1alpha in tauopathy (2017)](https://pubmed.ncbi.nlm.nih.gov/28222511/)
[Venturini et al., ERR in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33266451/)
[Yang et al., ERRgamma in dopaminergic neuron development (2018)](https://pubmed.ncbi.nlm.nih.gov/29876756/)
[Kim et al., ERRgamma in mitochondrial quality control (2019)](https://pubmed.ncbi.nlm.nih.gov/31197197/)
[Liu et al., ERRgamma and oxidative stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31781347/)
[Fan et al., ERRgamma in neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32887615/)
[Xiao et al., ERRgamma in metabolic dysfunction (2021)](https://pubmed.ncbi.nlm.nih.gov/34381732/)
[Kim et al., Targeting ERRgamma for therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35768992/)Clinical Implications
Biomarker Potential
ESRRG shows promise as a biomarker for neurodegenerative diseases:
Diagnostic Biomarkers:
- ESRRG expression levels in brain tissue correlate with disease stage
- Peripheral blood ESRRG mRNA as potential screening tool
- ESRRG genetic variants as risk stratification markers
Prognostic Biomarkers:
- ESRRG levels predict disease progression
- Mitochondrial function indicators
- Energy metabolism readouts
Therapeutic Biomarkers:
- Target engagement markers for ERRγ agonists
- Mitochondrial biogenesis indicators
- Metabolic function measurements
Clinical Trials and Drug Development
Current Status:
- No ESRRG-targeted drugs in clinical trials for neurodegeneration
- ESRRG agonists in development for metabolic diseases
- Preclinical validation ongoing for CNS applications
Clinical Development Considerations:
- BBB penetration is critical challenge
- dosing strategies for chronic treatment
- Combination approaches with mitochondrial protectants
Pharmacogenomics
ESRRG polymorphisms influence drug response:
| Genotype | Expression Level | Therapeutic Implication |
|----------|-----------------|------------------------|
| Variant A | Increased | May respond to antagonists |
| Variant B | Decreased | May benefit from agonists |
| Wild-type | Normal | Standard dosing |
Patient Stratification
ESRRG-based stratification for clinical trials:
- Expression-based patient selection
- Genotype-informed approaches
- Metabolic phenotype integration
Animal Models
Genetic Models
Knockout mice:
- Esrrg-/- mice are viable but show developmental defects
- Mitochondrial dysfunction in multiple tissues
- Behavioral changes reminiscent of neurodegenerative models
Conditional knockouts:
- Brain-specific deletion reveals neuronal functions
- Dopaminergic neuron-specific knockout models PD-like phenotypes
Transgenic models:
- ESRRG overexpression protects against metabolic stress
- Neuronal overexpression enhances mitochondrial function
Disease Models
Alzheimer's Disease Models:
- ESRRG expression altered in APP/PS1 mice
- ESRRG activation reduces amyloid pathology
- Improves cognitive function in AD models
Parkinson's Disease Models:
- ESRRG protects against MPTP toxicity
- Dopaminergic neuron protection observed
- Improves mitochondrial function
Therapeutic Development
Drug Candidates
ESRRG Agonists:
- GSK4716: Selective ERRγ agonist, used in preclinical studies
- DY131: ERRβ/γ agonist, neuroprotective effects
- CINT1: Novel activator in development
Mechanism of Action:
- PGC-1α coactivation
- Mitochondrial biogenesis
- Antioxidant gene expression
- Anti-inflammatory effects
Delivery Challenges
Blood-brain barrier: Most small molecules have limited CNS penetration
Target engagement: Measuring receptor activation in vivo
Specificity: Avoiding off-target effects on other nuclear receptorsCombination Therapies
ESRRG-based approaches may be combined with:
- [PGC-1α activators](/therapeutics/pgc1-alpha-targeted-therapies)
- Mitochondrial antioxidants (CoQ10, MitoQ)
- Metabolic modulators
- Anti-inflammatory agents
Summary
ESRRG encodes estrogen-related receptor gamma, a nuclear receptor with critical roles in mitochondrial biogenesis, energy metabolism, and neuroprotection. The receptor's involvement in Alzheimer's and Parkinson's disease pathogenesis through effects on mitochondrial function, oxidative stress, and neuroinflammation makes it an attractive therapeutic target. While ESRRG agonists show promise in preclinical models, challenges related to blood-brain barrier penetration and receptor selectivity remain. Further research is needed to validate ESRRG as a therapeutic target and develop brain-penetrant small molecules for neurodegenerative diseases.
Pathway Diagram
The following diagram shows the key molecular relationships involving ESRRG Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)